yocardial hypertrophy is associated with numerous metabolic changes, including substrate preference 1 and calcium regulation, alterations in cellular Ca 2+ transport and excitation -contraction coupling, 2-4 which may contribute to the inotropic-insensitive contractile dysfunction observed in cardiac hypertrophy. In particular, the preferred energy substrate of the hypertrophied myocardium is known to shift from fatty acids to glucose, 5 but the availability of glucose would be limited in the hypertrophied-failing heart. We previously demonstrated in a model of left ventricular (LV) hypertrophy that glucose transport improved myocardial contractile function, particularly post ischemia. 6-8 Abnormal excitationcontraction coupling is known to occur in the hypertrophied failing heart and is related to impaired sarcoplasmic reticulum (SR) Ca 2+ -ATPase (SERCA2), 9 Na + /Ca 2+ exchanger 10 and/or contractile protein. 11 However, the precise cellular mechanisms that are responsible for the changes in contractility and the alteration in cytosolic Ca 2+ ([Ca 2+ ]i) are largely unknown. Recent evidence suggests that glycolysis is important for the preservation of myocardial Ca 2+ homeostasis during -adrenergic stimulation, 12 and inhibition of glycolysis contributes to diastolic dysfunction in LV hypertrophy. 13 We also previously demonstrated in our model of LV hypertrophy that glucose transport into the myocytes was a critical limiting factor in the hypertrophied heart and that stimulation of glucose transport improved myocardial contractile function, especially post ischemia. 7 We hypothesized that the impaired glucose metabolism that is known to occur in the hypertrophied myocardium contributes to the SR Ca 2+ -ATPase dysfunction, which is subsequently followed by contractile dysfunction. To further determine the cellular mechanisms of abnormal calcium regulation and excitation -contraction coupling in the hypertrophied heart (aortic banding from 10 days of age), we evaluated myocardial mechanics by (1) serial echocardiograms in vivo; and (2) isolated Langendorff perfusion of 6-7-week-old hypertrophied hearts in response to dobutamine (20-150 ng/ml). The effects on myocardial contractility and intracellular calcium (Cai) handling of glycolytic inhibition with and without pyruvate, and inhibition of SR Ca 2+ -ATPase were also evaluated in isolated Langendorff perfused age-matched control (AMC) hearts. [Ca 2+ ]i was measured using fluorescence spectroscopy (Rhod-2) and the rate of [Ca 2+ ]i removal ( Ca,T1/2), and oxygen consumption (MV • O2) were also evaluated. SERCA2 expression was determined by Western immunoblotting.
yocardial hypertrophy is associated with numerous metabolic changes, including substrate preference 1 and calcium regulation, alterations in cellular Ca 2+ transport and excitation -contraction coupling, [2] [3] [4] which may contribute to the inotropic-insensitive contractile dysfunction observed in cardiac hypertrophy. In particular, the preferred energy substrate of the hypertrophied myocardium is known to shift from fatty acids to glucose, 5 but the availability of glucose would be limited in the hypertrophied-failing heart. We previously demonstrated in a model of left ventricular (LV) hypertrophy that glucose transport improved myocardial contractile function, particularly post ischemia. [6] [7] [8] Abnormal excitationcontraction coupling is known to occur in the hypertrophied failing heart and is related to impaired sarcoplasmic reticulum (SR) Ca 2+ -ATPase (SERCA2), 9 Na + /Ca 2+ exchanger 10 and/or contractile protein. 11 However, the precise cellular mechanisms that are responsible for the changes in contractility and the alteration in cytosolic Ca 2+ ([Ca 2+ ]i) are largely unknown. Recent evidence suggests that glycolysis is important for the preservation of myocardial Ca 2+ homeostasis during -adrenergic stimulation, 12 and inhibition of glycolysis contributes to diastolic dysfunction in LV hypertrophy. 13 We also previously demonstrated in our model of LV hypertrophy that glucose transport into the myocytes was a critical limiting factor in the hypertrophied heart and that stimulation of glucose transport improved myocardial contractile function, especially post ischemia. 7 We hypothesized that the impaired glucose metabolism that is known to occur in the hypertrophied myocardium contributes to the SR Ca 2+ -ATPase dysfunction, which is subsequently followed by contractile dysfunction. To further determine the cellular mechanisms of abnormal calcium regulation and excitation -contraction coupling in the hypertrophied heart (aortic banding from 10 days of age), we evaluated myocardial mechanics by (1) serial echocardiograms in vivo; and (2) isolated Langendorff perfusion of 6-7-week-old hypertrophied hearts in response to dobutamine (20-150 ng/ml). The effects on myocardial contractility and intracellular calcium (Cai) handling of glycolytic inhibition with and without pyruvate, and inhibition of SR Ca 2+ -ATPase were also evaluated in isolated Langendorff perfused age-matched control (AMC) hearts. [Ca 2+ ]i was measured using fluorescence spectroscopy (Rhod-2) and the rate of [Ca 2+ ]i removal ( Ca,T1/2), and oxygen consumption (MV • O2) were also evaluated. SERCA2 expression was determined by Western immunoblotting.
Animal Care and Use Committee. New Zealand White rabbits (aged 7-10 days) were used to create the model of left ventricular (LV) hypertrophy. After anesthesia was induced with ketamine sulfate (30 mg/kg im) and xylazine (0.5 mg/kg im), a left thoracotomy was performed under sterile conditions. A 2-0 silk suture was placed around the descending aorta just distal to the ligamentum arteriosum, taking care to make the suture just snug without causing stenosis of the aorta. After chest closure, air was removed from the thoracic cavity by catheter aspiration. After recovery from anesthesia, the animals were returned to their mothers and allowed to feed and grow in the normal manner. Thus, as the animals grew, an aortic coarctation gradually developed. At 6-7 weeks of age, the animals were killed to measure cardiac function and Cai. Agematched animals served as controls.
Echocardiography
At 3 weeks of age and then at 1-week intervals, 2-dimensional cross-sectional images and M-mode images of the left ventricle were obtained by echocardiography with simultaneous recording of the ECG and measurement of the LV short-axis dimensions by M-mode on hard copy at a paper speed of 100 mm/s. The LV epicardial and endocardial surfaces were traced by computer-aided off-line analysis on a bit-mapped digitizing tablet. End-diastolic (maximum dimension) and end-systolic (minimum dimension) LV wall thicknesses were determined using previously described methods. [14] [15] [16] The Mass/Volume (M/V) ratio was calculated, and the serial evaluation of the M/V ratio was expressed as the percentage change from the baseline.
Isolated Perfused Heart Model
At 6-7 weeks of age, animals were killed with an overdose of ketamine (150 mg/kg iv); heparin was also given (500 U/kg iv). The hearts were rapidly excised and retrogradely perfused at 80 mmHg constant pressure in the Langendorff mode with modified Krebs-Henseleit (K-H) buffer solution, as described previously. 6 Briefly, this buffer comprises: NaCl, 140 mmol/L; CaCl2, 1.25 mmol/L; KCl, 4.7 mmol/L; glucose, 11.0 mmol/L; MgSO4, 1.2 mmol/L; NaHCO3, 25 mmol/L; NaH2PO4, 0.5 mmol/L; bovine regular insulin, 10 U/L, was also included. The hearts were then rapidly perfused retrogradely through the aorta in the Langendorff mode at 80 mmHg constant pressure with 37°C K-H buffer that had been equilibrated with 95% O2-5% CO2 gas mixture and passed through a 0.2 m filter. The final buffer pH was 7.35-7.45, PO2 was 500-600 mmHg, and PCO2 was 30-40 mmHg. The pulmonary outflow tract was incised and cannulated for venous effluent collection. A latex fluid-filled balloon connected to a micromanometery catheter (Millar Instruments, Houston, TX, USA) was used for isovolumic LV function measurements. The balloon was inserted into the left ventricle and sewn to the mitral annulus to prevent herniation; balloon volume was varied with a calibrated, fluid-filled syringe. The atrioventricular node was destroyed and the hearts were paced at 150 beats/min by atrioventricular pacing wires sutured to the right atrium and the free wall of the right ventricle.
Peak developed LV pressure (Peak DevP) was measured at an LV end-diastolic pressure of 5 mmHg. Coronary flow was measured by timed collection of the coronary effluent through the cannula placed in the pulmonary artery. Oxygen content was calculated from the measured oxygen tension (ABL-3 Acid-Base Laboratory, Radiometer, Copenhagen, Denmark) of the aortic perfusate and the coronary venous effluent samples; myocardial oxygen consumption (MV • O2) was calculated as the measured arteriovenous oxygen difference multiplied by coronary flow and divided by the dry weight of the heart.
Experimental Protocol
After 30 min of stabilization, several experiments were performed. After dye loading and baseline data were obtained, 20-150 ng/min of dobutamine was infused for 2 min in both AMC and hypertrophied hearts. After a 5-min wash-out to clear the effects of the previous dobutamine infusion, another dobutamine infusion was performed. The effect of 2-deoxyglucose (2-DG), with and without pyruvate, and the selective SR Ca 2+ -ATPase inhibitor, thapsigargin (10 mol/L), were also tested in another 9 hearts. In the glycolysis inhibition experiment, modified K-H buffer containing 11 mmol/L glucose was replaced with low glucose K-H buffer in which 1 mmol/L glucose, and 3 mmol/L 2-DG with and without 10 mmol/L pyruvate were included as energy substrates.
Calcium Measurements
Measurement of beat-to-beat Cai transients was performed as previously described and validated in detail. 17 For all spectroscopic measurements, the hearts were perfused in a fluid-sealed chamber specially designed to minimize movement artifacts, abate the curvature of the epicardium, and maintain physiological conditions. The chamber was built in-house; it consisted of a front frame equipped with a 1-mm-thick optical window (sapphire; Oriel, Stratford, CT, USA) that made contact with the LV free wall. The perfusion chamber was equipped with ports for a perfusion cannula, an intracavity balloon, and pacing wires. The excitation light beam was focused on the surface of the heart by a biconvex lens to provide a 5-mm excitation spot. The emission fluorescence light was collected with a biconvex lens positioned at 90°to the incident excitation light beam. Reflected excitation light was collected by a third biconvex lens focused onto a flexible liquid light guide (Oriel) coupled to a second photomultiplier tube. The light guide and focusing lens were both positioned at 45°o n a vertical plane from the optical window and the plane of incident excitation light. A vertical plane was chosen to minimize the signal from the light reflex by the air -optical window and window -tissue interfaces (spectral reflection) and therefore increase the relative signal from the excitation light backscattered by the heart tissue itself. This backscatter reflectance signal was used to quantify the dye loading into the myocardium and to correct for the effects of motion. Similarly, the perfusion chamber with the optical window was positioned with a 30°angle of incidence (horizontal plane) to the excitation beam, which minimized the reflected excitation light from the airwindow and window -tissue interfaces that was seen by the fluorescence emission detector. After a 30-min stabilization period, hearts were loaded with cell-permeable Rhod-2 acetoxymethyl ester (Rhod-2 AM; 0.5 mg per 0.25 ml 100% ethanol infused over 2 min into the aortic root without recirculation) by perfusing the heart at 37°C, followed by a 15-min washout period to remove nonhydrolyzed dye. A modified spectrofluorometer (SLMAminco, Springfield, IL, USA) provided excitation light at 524 nm and measured emission light at 589 nm. Real-time acquisitions of 4 ms each (ie, approximately 100 data points per cardiac cycle) recorded every 5 s were digitized and stored. Because Rhod-2 has no spectral shift when it binds calcium, it is necessary to account for changes in tissue Rhod-2 concentration over time (eg, leakage or photobleaching), as well as differences in dye loading. To do this, F589 was corrected for tissue absorbance as follows. Excitation light was scanned at wavelengths between 524 nm (peak Rhod-2 absorbance in cardiac tissue) and 589 nm (reference wavelength at which there is insignificant Rhod-2 absorbance) and the ratio of reflected light at 524:589 was used to estimate tissue dye concentration. 15 The calcium fluorescence signal was also corrected for tissue autofluorescence by subtracting the fluorescence spectra of the heart prior to Rhod-2 loading from that of the Rhod-2 loaded heart. Instantaneous rationing of the fluorescent intensity (F) at 589 nm to reflected excitation light at 524 nm were done electronically to correct for heart motion. Calcium transient values were expressed as peak fluorescent intensity corrected for autofluorescence divided by the absorbance correction for dye concentration (F/A).
Following stabilization of dye loading and baseline signal acquisition, beating hearts were perfused in a stepwise fashion for 2 min each with K-H buffer containing 20, 50, 80 or 150 ng of dobutamine. In this way, the relationship of the inotropic effects on Cai and Cai to contractile force could be demonstrated. LV pressure and Rhod-2 fluorescence data were recorded simultaneously. All data analyses were performed using commercially available software (Sigma Plot, Jandel Scientific). The rate of the Cai transient decline during diastole, Ca was assessed by curve fitting to a monoexponential function as described previously 18 
Statistical Analysis
All values are reported as mean ± SEM. Data are taken from 6-8 experiments. Multiple group comparisons were made using analysis of variance followed by the Bonferroni procedure. Differences were considered significant at p<0.05 with adjustment made for multiple comparisons.
Results

Evaluation of the Hypertrophied Heart
The ratio of LV:body weight, which was used as an index of LV hypertrophy, was significantly higher in the hypertrophied hearts (4.3±0.9×10 -3 ) than in the AMC hearts (2.1±0.05×10 -3 ), suggesting well-developed LV hypertrophy (Table 1) .
Echocardiography
Serial echocardiography revealed that systolic peak wall stress had fallen to within the normal range at 4 weeks after the aortic banding and was accompanied by significantly increased M/V ratio (1.1±0.06 at 4 weeks vs 0.82±0.06 at 3 weeks; ie, compensated hypertrophy). Thereafter the M/V ratio progressively fell, resulting in an elevation of peak systolic wall stress, reflecting a failure of adequate hypertrophy (Fig 1) . Fractional shortening was also significantly reduced in the 5-week hypertrophied heart (22.0±4.0% vs 32.4±1.6% in AMC) with further deterioration in the following time course (15.1±4.0% in 7-week hypertrophied heart).
Cardiac Function and Oxygen Consumption (MV
• O2) Peak DevP tended to be lower in the hypertrophied heart (78±24 mmHg vs 99±2 mmHg in AMC), but was not statis- 
Fig 1. Peak systolic stress and mass/volume (M/V) ratio. (A)
Change in peak systolic stress in the aortic banding model. Aortic banding was performed at 1 week of age (age is expressed in weeks). *p<0.05 vs age-matched control. Peak systolic stress led to an increase in the M/V ratio. (B) Change in the M/V ratio in the hypertrophied heart (Hyp) and age-matched control heart (AMC). A temporal increase in the peak systolic stress at 3 weeks of age was followed by significant increase of the M/V ratio at 4 weeks of age. *p<0.05 vs age-matched control.
tically significant (Fig 2) because of the variability of DevP, suggesting a transition from compensated hypertrophied heart to decompensated heart (ie, failing heart). However, the myocardial contractile response to the stepwise change in dobutamine concentration was significantly different; for example, although there was an insignificant change in the hypertrophied heart (98±33 mmHg), a 30% increase was seen in the AMC heart (130±5 mmHg) with 150 ng of dobutamine. The maximal positive dp/dt and minimum dp/dt were also insignificantly lower in the hypertrophied heart because of variable data. The rate -pressure product (RPP) over the MV • O2, which was used as an index of mechanical efficiency, was not statistically different between the groups, suggesting that mechanical efficiency remained intact at the baseline in this model of the pressure overload hypertrophied myocardium (Table 2 ) with dobutamine challenge.
Intracellular Calcium
Systolic and diastolic Cai were both significantly higher in the hypertrophied heart than in the AMC heart (61±24 vs 38±3.0; 46±20 vs 26±1.5, respectively). The % change in Cai in response to the different doses of dobutamine was similar in both the hypertrophied and AMC hearts. The Ca was significantly slower in the hypertrophied heart (183±38 ms) than in the AMC heart (98±5 ms) (Fig 4) and did not improve with dobutamine administration in the hypertrophied heart (Fig 5) .
Western Immunoblotting
The level of SERCA2 protein was increased in the early hypertrophied heart at 5 weeks (Fig 6) , but then it significantly decreased (41±6.7 U.OD vs 33±3.0 U.OD AMC) by 6 weeks of age and was further decreased at 7 weeks of age (7.5±0.5 U.OD) (Fig 6) .
Glucose Inhibition by 2-DG and SR ATPase Inhibition by Thapsigargin
Chemical inhibition of glycolysis using 2-DG impaired Fig 2. Change in the developed pressure reaction to dobutamine in both hypertrophied and age-matched control hearts. The response to dobutamine was weaker in the hypertrophied heart than in the agematched control heart, particularly with low-dose dobutamine. *p<0.05 vs age-matched control. The change in calcium tau with a high dose of dobutamine (150 ng) was significantly greater in the hypertrophied heart than in the age-matched control heart, suggesting slower cytosolic calcium removal. Dobutamine insignificantly improved calcium tau in the hypertrophied heart. *p<0.05 vs age-matched control heart. Cai, including a slower Ca (152±14 ms vs 98±8 ms in AMC), and increased Cai (46±24 vs 36±21 in AMC) within 20 min, followed by functional deterioration of the myocardium (Fig 7) . Pyruvate, which is an intermediate product of glycolysis, caused almost no further deterioration in the effects on cardiac function and Cai from the 2-DG administration (Fig 7) .
The specific SR Ca 2+ -ATPase inhibitor, thapsigargin, increased the Cai level (43±15 vs 34±12 in AMC) as well as slowing calcium removal from the cytosol (167±24 ms vs 100±8 ms in AMC), which mimicked the effects seen in the pressure overload hypertrophied myocardium (Fig 8) .
Discussion
An important piece of information from this study is that the immature pressure overload hypertrophied heart has functional deterioration of the myocardium, along with progressive impairment of Cai handling associated with a significant decrease of SERCA2 protein. Acute inhibition of SERCA2 resulted in slower [Ca 2+ ]i removal, as well as an increase in the Cai level, effects that which mimicked the pressure overload hypertrophied heart. Glucose inhibition also impaired Cai handling and pyruvate administration almost completely overcame this impairment.
Glucose is a very important substrate for energy production in pathological conditions such as myocardial hypertrophy, ischemia -reperfusion and inflammatory reactions. In particular, the substrate preference for energy production in the hypertrophied heart is known to shift more towards glucose than fatty acids. 1 We previously reported that impaired glucose transporter activity was an early indicator of progression of heart failure in the pressure overload hypertrophied heart. 8 ATP from glycolysis is important for maintaining various protein functions on the sarcolemma, such as the ATP-sensitive K + channel 19 and SERCA2, 12 and impairment of these proteins may cause ionic imbalances.
Calcium is an important molecule for myocardial contraction and is regulated by many membrane proteins, such as the ryanodine receptor, SR Ca 2+ -ATPase, voltage gated calcium channel (dihydropyridine (DHPT) sensitive receptors) and the Na + /Ca 2+ exchanger. 20 Intracellular calcium is mostly stored in the SR and mitochondria, and the major calcium release channel is the ryanodine receptor, and Cai is restored by SR Ca 2+ -ATPase. 21 Sumida and et al 22 reported that in myocytes from a compensated hypertrophy heart model there was an adaptive increase in the amplitude of Cai transients with reduced myofilament responsiveness to increased Cai, which is interesting because this may be an early phenomenon in the transition from compensation to decompensation caused by the SR dysfunction associated with impaired glucose metabolism. It is believed that the function of the Na + /Ca 2+ exchanger is supplemental to the function of SR Ca 2+ -ATPase, but the function of Na + /Ca 2+ is enhanced in the failing heart after the loss of SERCA2 as a compensatory mechanism in the end-stage failing heart. 23, 24 There have been several reports of a change in Cai levels in the hypertrophied failing heart in association with contractile dysfunction, such as impaired calcium handling, and less sensitivity of contractile proteins to calcium. Downregulation 9 or decreased activity 10 of SERCA2 is found in the decompensated failing heart and might be associated with contractile dysfunction. Glycolytic ATP is very important for maintaining SERCA2 function, 12, 17, 18 as well as other ionic channels such as K + -ATPase. 19 Increased ADP concentration through the inhibition of glycolysis contributes to diastolic dysfunction in normal rat hearts. 13 Functional coupling of glycolytic ATP and SR Ca 2+ -ATPase in the normal heart has been suggested by Xu et al. 25 We previously reported that there was significant change in glucose uptake and phosphorylation activity in the early decompensated hypertrophied heart, but no significant change in the glucose transporter protein GLUT4. 7, 8 The most plausible explanation for these results is that the decreased glucose utilization affects SERCA2 activity as well as the SERCA2 protein. Interestingly, this is true in other cell type: inhibition of glycolysis by 2-deoxy-D-glucose increases Cai in pulmonary arterial smooth muscle cells. 26 Vanadyl sulfate, which is +IV valence vanadate, has an insulin-like action that promotes glucose uptake and was used experimentally to restore glucose metabolism. It has also been used clinically for non-insulin dependent diabetes patients. We previously reported that this compound effectively promoted glucose uptake and phosphorylation and improved ischemic tolerance in the pressure overload hypertrophied heart. Pyruvate, a metabolic product of glycolysis, is known to have variable actions, including increasing the energy potential, increasing cardiac mechanical performance, chelating inorganic phosphates and oxyradical scavenging via direct neutralization of peroxide and/or enhancement of the intracellular glutathione/NADPH antioxidant system. It was ascertained that myocardial function as well as Cai handling was restored by simultaneous pyruvate administration with glycolytic inhibition. Pyruvate is a final product of glycolysis and is oxidized and decarboxylated to form an acetyl group, which, then combined with coenzyme A (acetyl-CoA), enters the TCA cycle. This suggests that the total energy potential is important for maintaining the calcium handling in myocytes rather than locally produced ATP.
We conclude that in a model of advanced pressure overload hypertrophy that is similar to many congenital heart defects, contractile failure and inotrope insensitivity were associated with increased [Ca 2+ ]i slow decline or removal of calcium during diastole by SR, and reduced sensitivity of the contractile proteins to Ca 2+ (decreased calcium-activated force generation). These changes occur in association with downregulation of SR Ca 2+ -ATPase. Strategies known to restore SR Ca 2+ -ATPase function and/or expression (eg, triiodothyronine) or improve glycolysis (eg, pyruvate or vanadate) may be useful in improving functional recovery in the hypertrophied heart, especially after ischemia.
